La maladie de Parkinson au Canada (serveur d'exploration) - Exploration (Accueil)

Index « Keywords » - entrée « D2 Dopamine receptor »
Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.
D2 < D2 Dopamine receptor < D2 agonist  Facettes :

List of bibliographic references indexed by D2 Dopamine receptor

Number of relevant bibliographic references: 52.
[20-40] [0 - 20][0 - 50][40-51][40-60]
Ident.Authors (with country if any)Title
003332 (2001) ABDALLAH HADJ TAHAR [Canada] ; Anna Ekesbo [Suède] ; Laurent Gregoire [Canada] ; Evelyne Bangassoro [Canada] ; Kjell A. Svensson [États-Unis] ; Joakim Tedroff [Suède] ; Paul J. Bedard [Canada]Effects of acute and repeated treatment with a novel dopamine D2 receptor ligand on L-DOPA-induced dyskinesias in MPTP monkeys
003351 (2001) Raul De La Fuente-Fernandez [Canada] ; Jian-Qiang Lu [Canada] ; Vesna Sossi [Canada] ; Salma Jivan [Canada] ; Michael Schulzer [Canada] ; James E. Holden [États-Unis] ; Chong S. Lee [Canada] ; Thomas J. Ruth [Canada] ; Donald B. Calne [Canada] ; A. Jon Stoessl [Canada]Biochemical variations in the synaptic level of dopamine precede motor fluctuations in Parkinson's disease : PET evidence of increased dopamine turnover
003557 (2000) ABDALLAH HADJ TAHAR [Canada] ; Laurent Gregoire [Canada] ; Evelyne Bangassoro [Canada] ; Paul J. Bedard [Canada]Sustained cabergoline treatment reverses levodopa-induced dyskinesias in parkinsonian monkeys
003562 (2000) M. Goulet [Canada] ; R. Grondin [Canada] ; M. Morissette [Canada] ; S. Maltais [Canada] ; P. Falardeau [Canada] ; P. J. Bedard [Canada] ; T. Di Paolo [Canada]Regulation by chronic treatment with cabergoline of dopamine D1 and D2 receptor levels and their expression in the striatum of Parkinsonian-Monkeys
003571 (2000) P. Seeman [Canada] ; D. Nam [Canada] ; C. Ulpian [Canada] ; I. S. C. Liu [Canada] ; T. Tallerico [Canada]New dopamine receptor, D2Longer, with unique TG splice site, in human brain
003599 (2000) O. Rascol [France] ; D. J. Brooks [Royaume-Uni] ; A. D. Korczyn [Israël] ; P. P. De Deyn [Belgique] ; C. E. Clarke [Royaume-Uni] ; A. E. Lang [Canada]A five-year study of the incidence of dyskinesia in patients with early parkinson's disease who were treated with ropinirole or levodopa
003681 (1999) Frédéric Calon ; Marc Morissette ; Martin Goulet ; Richard Grondin ; Pierre J. Blanchet ; Paul J. Bédard ; Thérèse Di Paolo [Canada]Chronic D1 and D2 dopaminomimetic treatment of MPTP-denervated monkeys: effects on basal ganglia GABAA/benzodiazepine receptor complex and GABA content
003796 (1999) M. C. Evans [États-Unis] ; A. Pradhan [Canada] ; S. Venkatraman [États-Unis] ; W. H. Ojala [États-Unis] ; W. B. Gleason [États-Unis] ; R. K. Mishra [Canada] ; R. L. Johnson [États-Unis]Synthesis and dopamine receptor modulating activity of novel peptidomimetics of L-prolyl-L-leucyl-glycinamide featuring α, α-disubstituted amino acids
003801 (1999) D. E. Hobson [Canada] ; E. Pourcher [Canada] ; W. R. W. Martin [Canada]Ropinirole and pramipexole, the new agonists
003803 (1999) Nicolaas Paul L. G. Verhoeff [Canada]Radiotracer imaging of dopaminergic transmission in neuropsychiatric disorders
003831 (1999) E. M. Khalil [États-Unis] ; W. H. Ojala [États-Unis] ; A. Pradhan [Canada] ; V. D. Nair [Canada] ; W. B. Gleason [États-Unis] ; R. K. Mishra [Canada] ; R. L. Johnson [États-Unis]Design, synthesis, and dopamine receptor modulating activity of spiro bicyclic peptidomimetics of L-prolyl-L-leucyl-glycinamide
003832 (1999) R. Grondin [Canada] ; V. D. Doan ; L. Gregoire ; P. J. BedardD1 receptor blockade improves L-dopa-induced dyskinesia but worsens parkinsonism in MPTP monkeys
003A28 (1998) V. P. Calabrese [Canada] ; K. A. Lloyd [Canada] ; P. Brancazio [Canada] ; E. Cefali [États-Unis] ; P. Martin [États-Unis] ; J. Jr Wall [États-Unis] ; D. Sica [États-Unis]N-0923, a novel soluble dopamine D2 agonist in the treatment of parkinsonism
003B34 (1997) M. Goulet [Canada] ; M. Morissette [Canada] ; F. Calon [Canada] ; P. J Blanchet [Canada] ; P. Falardeau [Canada] ; P. J Bédard [Canada] ; T. Di Paolo [Canada]Continuous or pulsatile chronic D2 dopamine receptor agonist (U91356A) treatment of drug-naive 4-phenyl-1,2,3,6-tetrahydropyridine monkeys differentially regulates brain D1 and D2 receptor expression: in situ hybridization histochemical analysis
003C40 (1997) R. Grondin [Canada] ; P. J. Bedard [Canada] ; D. R. Britton [États-Unis] ; K. Shiosaki [États-Unis]Potential therapeutic use of the selective dopamine D1 receptor agonist, A-86929 : An acute study in parkinsonian levodopa-primed monkeys
003C66 (1997) M. Guttman [Canada]Double-blind comparison of pramipexole and bromocriptine treatment with placebo in advanced Parkinson's disease
003C67 (1997) P. W. Baures [États-Unis] ; W. H. Ojala [États-Unis] ; W. J. Costain [Canada] ; M. C. Ott [Canada] ; A. Pradhan [Canada] ; W. B. Gleason [États-Unis] ; R. K. Mishra [Canada] ; R. L. Johnson [États-Unis]Design, synthesis, and dopamine receptor modulating activity of diketopiperazine peptidomimetics of L-prolyl-L-leucylglycinamide
003E69 (1996) R. Grondin [Canada] ; M. Goulet [Canada] ; T. Di Paolo [Canada] ; P. J. Bédard [Canada]Cabergoline, a long-acting dopamine D2-like receptor agonist, produces a sustained antiparkinsonian effect with transient dyskinesias in parkinsonian drug-naive primates
003E89 (1996) N. Galvez-Jimenez [Canada] ; A. E. Lang [Canada]Perioperative problems in Parkinson's disease and their management : Apomorphine with rectal domperidone
003F76 (1995) Céline Gagnon [Canada] ; Baltazar Gomez-Mancilla [Canada] ; Rudolf Markstein [Suisse] ; Paul J. Bédard [Canada] ; Thérèse Di Paolo [Canada]Effect of adding the D-1 agonist CY 208–243 to chronic bromocriptine treatment of MPTP-monkeys: Regional changes of brain dopamine receptors
004027 (1995) F. Calon [Canada] ; M. Goulet [Canada] ; P. J. Blanchet [Canada] ; J. C. Martel [Canada] ; M. F. Piercey [États-Unis] ; P. J. Be Dard [Canada] ; T. Di Paolo [Canada]Levodopa or D2 agonist induced dyskinesia in MPTP monkeys: correlation with changes in dopamine and GABAA, receptors in the striatopallidal complex

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/Main/Exploration
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/KwdEn.i -k "D2 Dopamine receptor" 
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/KwdEn.i  \
                -Sk "D2 Dopamine receptor" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd 

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Canada
   |area=    ParkinsonCanadaV1
   |flux=    Main
   |étape=   Exploration
   |type=    indexItem
   |index=    KwdEn.i
   |clé=    D2 Dopamine receptor
}}

Wicri

This area was generated with Dilib version V0.6.29.
Data generation: Thu May 4 22:20:19 2017. Site generation: Fri Dec 23 23:17:26 2022